Structure via PubChem · Public domain (PubChem)
prasugrel
Sign in to saveAlso known as CS-747, Effient®, Efient®, Effient
Prasugrel, sold under the brand names Effient and Efient, is a medication used to prevent formation of blood clots. It is a platelet inhibitor and an irreversible antagonist of P2Y12 ADP receptors and is of the thienopyridine drug class. It was developed by Daiichi Sankyo Co. and produced by Ube and marketed in the United States in cooperation with Eli Lilly and Company.
Chemical data
- Formula
- C20H20FNO3S
- Molecular weight
- 373.4 g/mol
- IUPAC name
- [5-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-6,7-dihydro-4H-thieno[3,2-c]pyridin-2-yl] acetate
- SMILES
- CC(=O)OC1=CC2=C(S1)CCN(C2)C(C3=CC=CC=C3F)C(=O)C4CC4
- InChIKey
- DTGLZDAWLRGWQN-UHFFFAOYSA-N
- XLogP
- 3.6
- Polar surface area
- 74.9 Ų
- H-bond donors
- 0
- H-bond acceptors
- 6
- Formal charge
- 0
via PubChem
Wikidata facts
- Mass
- 373.114793
Show 4 more facts
- chemical formula
- C₂₀H₂₀FNO₃S
- canonical SMILES
- CC(=O)OC1=CC2=C(S1)CCN(C2)C(C3=CC=CC=C3F)C(=O)C4CC4
- defined daily dose
- 10
- Commons category
- Prasugrel
via Wikidata · CC0
~7 min read
Article
13 sectionsContents
- Medical uses
- Approval status
- Contraindications
- Adverse effects
- Interactions
- Pharmacology
- Mechanism of action
- Pharmacodynamics
- Pharmacokinetics
- Chemistry
- References
- Further reading
- External links
Prasugrel, sold under the brand names Effient and Efient, is a medication used to prevent formation of blood clots. It is a platelet inhibitor and an irreversible antagonist of P2Y12 ADP receptors and is of the thienopyridine drug class. It was developed by Daiichi Sankyo Co. and produced by Ube and marketed in the United States in cooperation with Eli Lilly and Company.
Prasugrel was approved for use in the European Union in February 2009, and in the US in July 2009, for the reduction of thrombotic cardiovascular events (including stent thrombosis) in people with acute coronary syndrome (ACS) who are to be managed with percutaneous coronary intervention (PCI).